Caribou Biosciences, Inc.（CRBU）股價、財務與研究

盤中時間採用ET。市場資料可能有所延遲。

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

35/ 100

GoAI評分

Sell

Trim exposure — unfavorable risk-reward

估值

42

Fair Value

動能

57

Neutral

情緒

43

Mixed

風險韌性

21

High Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考，並非投資建議。

公司概況

公司網站

Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Rachel E. Haurwitz
上市以來: 2021年7月23日
僱員: 97

市場位置

成交量: 47.09萬; 0.26× 平均值
平均成交量: 178.87萬; 日均成交量
市值: 1.64億 USD
貝塔: 2.28; 市場參考 1

財務數據

財務快照

估值與收益率

本益比（TTM）: -1.53×
股價淨值比（TTM）: 1.7×
股價營收比（TTM）: 16.35×
股息率: 0.00%

獲利能力和效率

毛利率: -129.70%
營業利益率: -1090.90%
淨利潤率: -1030.42%

財務健康

負債權益比: 0.27×

財報歷史與展望

EPS優於預期率: 73%; 優於預期8次、低於預期2次、符合預期1次
平均EPS意外幅度: +1.73%; 11 類似報告
最新每股收益結果: -0.24; 預估-0.32 · 優於預期25.93%

EPS：實際值與預估值

近期已公布業績

實際值預估值

營收：實際值與預估值

近期已公布業績

實際值預估值

分析師評級

第三方分析師預期可能變動，並非 GoAI 建議。

分析師目標價

平均目標

US$5.00

上漲空間 202.33%

過去 12 個月12個月預測最高：US$7.00平均的：US$5.00最低：US$3.00

近期分析師行動

6 機構

Evercore ISI GroupmaintainOutperform2026年3月9日

Truist SecuritiesmaintainBuy2024年5月16日

CRBU 訊息

defenseworld.net2026年8月17日

Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $7.75

Caribou Biosciences, Inc. (NASDAQ: CRBU - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are currently covering the company, MarketBeat.com reports. One investment…

閱讀原始碼

zacks.com2026年8月13日

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.35 per share a year ago.

閱讀原始碼

globenewswire.com2026年8月13日

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers…

閱讀原始碼

zacks.com2026年7月9日

Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?

Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.

閱讀原始碼

globenewswire.com2026年6月29日

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's…

閱讀原始碼

globenewswire.com2026年6月11日

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient administration and…

閱讀原始碼